Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 10-2013 | 12-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,259 | 207 | N/A | 52 | N/A |
| Receivables | N/A | N/A | N/A | 25 | 7 |
| Other current assets | 36 | 37 | 0 | 13 | 0 |
| TOTAL | $3,454 | $308 | $N/A | $106 | $7 |
| Non-Current Assets | |||||
| PPE Net | 13 | 21 | N/A | 40 | 0 |
| Other Non-Current Assets | 44 | 19 | 0 | 0 | 0 |
| TOTAL | $57 | $40 | $N/A | $40 | $N/A |
| Total Assets | $3,511 | $348 | $N/A | $146 | $7 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 125 | 410 | 2 | 15 | 0 |
| Accrued Expenses | 372 | 291 | 180 | N/A | 0 |
| Other current liabilities | 84 | 100 | N/A | N/A | 0 |
| TOTAL | $582 | $801 | $182 | $62 | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,455 | 0 | 0 | 0 | 0 |
| TOTAL | $2,458 | $1 | $N/A | $N/A | $N/A |
| Total Liabilities | $3,040 | $802 | $182 | $62 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 80 | 65 | N/A | N/A | N/A |
| Common Shares | 20 | 16 | 1 | 4 | N/A |
| Retained earnings | -7,759 | -2,917 | -183 | -3 | N/A |
| Other shareholders' equity | 2,123 | 190 | 0 | 0 | 0 |
| TOTAL | $471 | $-454 | $-182 | $83 | $N/A |
| Total Liabilities And Equity | $3,511 | $348 | $0 | $146 | $0 |